Astellas Pharma
Search results
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world.
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in 29 countries/regions around the world. With more than 120 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Daiichi Sankyo Company, Limited ( Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. [3] . The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo is an innovative global healthcare company based in Japan underpinned by its Purpose: “To contribute to the enrichment of quality of life around the world”.
5 days ago · About Daiichi Sankyo . Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new
4 days ago · The U.S. Food and Drug Administration declined to approve Merck and Japan-based Daiichi Sankyo's lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like ...
Oct 19, 2023 · BASKING RIDGE, N.J. & RAHWAY, N.J., October 19, 2023 – Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd ...
For people affected by cancer, Daiichi Sankyo turns hope into possibility. Possibility into reality. Our collective craft is medicine. We’re transforming how cancer and other disease are treated. More than 120 year of heritage inspires us to meet new challenges.
6 days ago · Daiichi's lung cancer ADC rejected by FDA in blow to first project under Merck partnership. By Angus Liu Jun 26, 2024 10:56pm. Merck & Co. Daiichi Sankyo antibody-drug conjugates Complete Response ...
5 days ago · Merck and Daiichi Sankyo supported their Biologics License Application with data from HERTHENA-Lung01 study, a pivotal Phase II study that enrolled 225 patients who experienced disease progression after treatment with an EGFR tyrosine kinase inhibitor and platinum-based chemotherapy. Results from HERTHENA-Lung01 showed an objective response rate of 29.8%, including one patient who achieved complete response and 66 patients who reached partial response. ...
